Sentinel lymph node biopsy in patients with ductal carcinoma in situ: A proposal

Kelly M. McMasters, Celia Chao, Sandra L. Wong, Robert C G Martin, Michael J. Edwards

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Sentinel lymph node (SLN) biopsy for the treatment of ductal carcinoma in situ (DCIS) is not necessary and generally should be limited to those patients with a core needle biopsy diagnosis of DCIS who are undergoing mastectomy. Used in this way, SLN biopsy will spare the majority of patients with occult invasive tumor the need for axillary lymph node dissection.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalCancer
Volume95
Issue number1
DOIs
StatePublished - Jul 1 2002
Externally publishedYes

Fingerprint

Sentinel Lymph Node Biopsy
Carcinoma, Intraductal, Noninfiltrating
Large-Core Needle Biopsy
Mastectomy
Lymph Node Excision
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

McMasters, K. M., Chao, C., Wong, S. L., Martin, R. C. G., & Edwards, M. J. (2002). Sentinel lymph node biopsy in patients with ductal carcinoma in situ: A proposal. Cancer, 95(1), 15-20. https://doi.org/10.1002/cncr.10641

Sentinel lymph node biopsy in patients with ductal carcinoma in situ : A proposal. / McMasters, Kelly M.; Chao, Celia; Wong, Sandra L.; Martin, Robert C G; Edwards, Michael J.

In: Cancer, Vol. 95, No. 1, 01.07.2002, p. 15-20.

Research output: Contribution to journalArticle

McMasters, KM, Chao, C, Wong, SL, Martin, RCG & Edwards, MJ 2002, 'Sentinel lymph node biopsy in patients with ductal carcinoma in situ: A proposal', Cancer, vol. 95, no. 1, pp. 15-20. https://doi.org/10.1002/cncr.10641
McMasters, Kelly M. ; Chao, Celia ; Wong, Sandra L. ; Martin, Robert C G ; Edwards, Michael J. / Sentinel lymph node biopsy in patients with ductal carcinoma in situ : A proposal. In: Cancer. 2002 ; Vol. 95, No. 1. pp. 15-20.
@article{0b867a6d0a41470cb18c84da0a4120db,
title = "Sentinel lymph node biopsy in patients with ductal carcinoma in situ: A proposal",
abstract = "Sentinel lymph node (SLN) biopsy for the treatment of ductal carcinoma in situ (DCIS) is not necessary and generally should be limited to those patients with a core needle biopsy diagnosis of DCIS who are undergoing mastectomy. Used in this way, SLN biopsy will spare the majority of patients with occult invasive tumor the need for axillary lymph node dissection.",
author = "McMasters, {Kelly M.} and Celia Chao and Wong, {Sandra L.} and Martin, {Robert C G} and Edwards, {Michael J.}",
year = "2002",
month = "7",
day = "1",
doi = "10.1002/cncr.10641",
language = "English (US)",
volume = "95",
pages = "15--20",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Sentinel lymph node biopsy in patients with ductal carcinoma in situ

T2 - A proposal

AU - McMasters, Kelly M.

AU - Chao, Celia

AU - Wong, Sandra L.

AU - Martin, Robert C G

AU - Edwards, Michael J.

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Sentinel lymph node (SLN) biopsy for the treatment of ductal carcinoma in situ (DCIS) is not necessary and generally should be limited to those patients with a core needle biopsy diagnosis of DCIS who are undergoing mastectomy. Used in this way, SLN biopsy will spare the majority of patients with occult invasive tumor the need for axillary lymph node dissection.

AB - Sentinel lymph node (SLN) biopsy for the treatment of ductal carcinoma in situ (DCIS) is not necessary and generally should be limited to those patients with a core needle biopsy diagnosis of DCIS who are undergoing mastectomy. Used in this way, SLN biopsy will spare the majority of patients with occult invasive tumor the need for axillary lymph node dissection.

UR - http://www.scopus.com/inward/record.url?scp=0036644987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036644987&partnerID=8YFLogxK

U2 - 10.1002/cncr.10641

DO - 10.1002/cncr.10641

M3 - Article

C2 - 12115311

AN - SCOPUS:0036644987

VL - 95

SP - 15

EP - 20

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -